

Zevin Asset Management, LLC

AbbVie Inc (ABBV)
Shareholder Proposal No. 5:
Report on AbbVie's Lobbying Expenses

To AbbVie Stockholders:

Zevin Asset Management, a registered investment advisor, along with co-filers Congregation of Sisters of St. Agnes, First Affirmative Financial Network, Friends Fiduciary Corp, and Sisters of Charity of the Blessed Virgin Mary, urge stockholders to vote FOR Item 5 at the AbbVie stockholder meeting on April 29, 2019.¹

The proposal asks AbbVie to prepare an annual report on its lobbying.

Resolved, the stockholders of AbbVie request the preparation of a report, updated annually, disclosing:

1. Company policy and procedures governing lobbying, both direct and indirect, and grassroots lobbying communications.
2. Payments by AbbVie used for (a) direct or indirect lobbying or (b) grassroots lobbying communications, in each case including the amount of the payment and the recipient.
3. AbbVie's membership in and payments to any tax-exempt organization that writes and endorses model legislation.
4. Description of management's and the Board's decision making process and oversight for making payments described in sections 2 and 3 above.

The proposal is part of an ongoing investor campaign² for greater corporate political spending disclosure. Transparency and accountability in corporate spending to influence public policy are in the best interests of AbbVie stockholders. Without a clear system ensuring accountability, corporate assets can be used to promote public policy objectives which can pose risks AbbVie's reputation to the detriment of stockholder value.

Reputation: Corporate Reputation Is an Important Component of Stockholder Value

- According to a Conference Board study, companies with a high reputation rank perform better financially than lower ranked companies. Executives also find it is much harder to recover from a reputational failure than to build and maintain reputation.³
- In a 2014 Deloitte survey, 87 percent of executives rated reputation risk as more important or much more important than other strategic risks their companies are facing, and 88 percent said their companies are explicitly focusing on managing reputation risk.⁴

¹ This communication is an exempt proxy solicitation submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required under the terms of the Rule, but is made voluntarily in the interest of public disclosure and consideration of these important issues. This is not a solicitation of authority to vote your proxy and Zevin Asset Management, LLC will not accept proxies if sent. Zevin Asset Management, LLC urges shareholders to vote for the proposals discussed in this communication following the instructions provided on management's proxy mailing. The cost of this communication is being borne entirely by Zevin Asset Management, LLC.

² "Institutional Investors Continue to Press Companies for Disclosure of Lobbying in 2019," [AFSCME & Walden Asset Management](https://waldenassetmgmt.com/wp-content/uploads/2019/02/Announcement-of-2019-lobbying-resolutions.pdf), February 27, 2019, <https://waldenassetmgmt.com/wp-content/uploads/2019/02/Announcement-of-2019-lobbying-resolutions.pdf>, accessed March 28, 2019.

³ "Reputation Risk," [The Conference Board](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1077894), 2007, p. 6, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1077894.

⁴ "2014 Global Survey on Reputation Risk," Deloitte, p. 4, https://www2.deloitte.com/content/dam/Deloitte/pl/Documents/Reports/pl_Reputation_Risk_survey_EN.pdf.

Federal Lobbying – AbbVie Spends Millions Each Year

- AbbVie spent \$11,760,000 in 2017 and 2018 on federal lobbying activities.
- And since 2013, AbbVie has spent more than \$32 million on federal lobbying.

State Lobbying – Information on AbbVie’s Spending Difficult to Obtain

- Obtaining comprehensive state lobbying information is described by an expert as “nearly impossible” given “the ‘Byzantine’ manner in which the data is captured and made available online” which effectively buries information at many states.⁵
- AbbVie’s state-level lobbying spending is likely significant. In 2017, AbbVie had as many as 83 lobbyists registered to lobby in 19 states.⁶
- In California, AbbVie spent over \$2.2 million from 2013 – 2018 on lobbying.⁷

Trade Association Blind Spot

- Corporations make payments to trade associations that are used to lobby indirectly on their behalf without specific disclosure or accountability. Trade associations spend hundreds of millions to lobby. For example, the US Chamber of Commerce has spent more than \$1.5 billion since 1998.⁸
- AbbVie stockholders face a trade association blind spot, as AbbVie does not disclose the portions of its payments to trade associations that are used for lobbying.
- AbbVie currently lists 2017 memberships⁹ in eight trade associations, including the Biotechnology Industry Association, the California Life Sciences Association, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Chamber of Commerce. These four trade associations spent over \$133 million on federal lobbying for 2018,¹⁰ yet stockholders have no way to know how much of this is comprised of AbbVie’s payments.
- And AbbVie’s current disclosure fails to disclose membership in at least four trade associations and two social welfare groups that spent \$1,747,417 million on federal lobbying for 2018, including the Alliance for a Stronger FDA, the Alliance for Patient Access, the Healthcare Distribution Alliance, the Massachusetts Biotechnology Council and the National Health Council.¹¹
- We believe AbbVie’s trade association memberships and payments used for lobbying pose reputational risks. For example, AbbVie believes patients need access to affordable medicines¹², yet it helps fund PhRMA’s opposition to lower drug price initiatives.¹³ And AbbVie is committed to having a positive impact on societies around the world¹⁴, yet the Chamber has worked to block global antismoking laws.¹⁵ And of AbbVie’s non-disclosed trade associations, the Alliance for Patient Access and the Healthcare Distribution Alliance have attracted negative scrutiny for their roles in passing legislation that weakened the Drug Enforcement Administration’s ability to stop suspicious drug shipments by distributors, thereby exacerbating the opioid crisis.¹⁶

⁵ “Wal-Mart Improves Lobbying Disclosure after Stockholder Push,” Reuters, May 13, 2015, <https://www.reuters.com/article/us-wal-mart-stores-disclosure-lobbying-e/exclusive-wal-mart-improves-lobbying-disclosure-after-stockholder-push-idUSKBN0NY0AH20150513>.

⁶ National Institute on Money in State Politics, <https://www.followthemoney.org/>, accessed March 28, 2019.

⁷ <http://cal-access.sos.ca.gov/Lobbying/Employers/Detail.aspx?id=1354351&view=activity&session=2017>

⁸ <https://www.opensecrets.org/lobby/top.php?indexType=s&showYear=2018>, accessed March 19, 2019.

⁹ <https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/AbbVie-Trade-Association-Membership-over-50M-2017.pdf>

¹⁰ OpenSecrets.org, (Biotechnology Industry Association - \$9,870,000, California Life Sciences Association - \$500,000, Pharmaceutical Research and Manufacturers of America – \$27,989,250, the Chamber of Commerce - \$94,800,000), accessed March 28, 2019.

¹¹ OpenSecrets.org, (the Alliance for a Stronger FDA (501c4), <https://strengthenfda.org/members/>, \$500,000, the Alliance for Patient Access (501c4), <http://1yh21u3cjptv3xjder1dco9mx5s.wpengine.netdna-cdn.com/wp-content/uploads/2018/01/AfPADonorsJanaury2018.pdf>, \$120,000, the Healthcare Distribution Alliance, <https://www.hda.org/about/membership/manufacturer>, \$1,234,042, Massachusetts Biotechnology Council, <https://www.massbio.org/member?category=biotechnology&subcategory=all&therapeuticArea=all&page=1>, \$80,000, National Health Council, <http://www.nationalhealthcouncil.org/about-nhc/membership-directory>, \$13,375, State Government Affairs Council, <http://www.sgac.org/regular-members---corporations-and-trade-associations.html>), websites accessed March 28, 2019.

¹² <https://www.abbvie.com/uploads/PDFs/our-commitment-to-access-to-medicines-2.pdf>

¹³ “PhRMA Spends Record Amount on Lobbying Amid Drug Pricing Fights,” The Hill, April 20, 2018, <https://thehill.com/policy/healthcare/384176-phrma-spends-record-amount-on-lobbying-amid-drug-pricing-fights>.

¹⁴ <https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/our-commitment-to-the-environment-health-and-safety.pdf>

¹⁵ “U.S. Chamber Works Globally to Fight Antismoking Measures,” New York Times, June 30, 2015, <https://www.nytimes.com/2015/07/01/business/international/us-chamber-works-globally-to-fight-antismoking-measures.html>.

¹⁶ “Opioid Lobbyist Left a Digital Fingerprint on a Campaign by ‘Patient Advocates,’” The Intercept, October 22, 2017, <https://theintercept.com/2017/10/22/opioid-lobbyist-left-a-digital-fingerprint-on-a-campaign-by-patient-advocates/>.

GRI Signatories Are Reporting Significant Lobbying and Public Policy Issues

- Many companies are signatories to the Global Reporting Initiative (GRI) and use the standards to help guide its sustainability reporting.
- GRI Standard 415: Public Policy¹⁷ “addresses the topic of public policy. This includes an organization’s participation in the development of public policy, through activities such as lobbying and making financial or in-kind contributions to political parties, politicians, or causes.”
- Under GRI Standard 415, a company “should report:
 - o (1) the significant issues that are the focus of its participation in public policy development and lobbying;
 - o (2) the company’s stance on these issues, and any differences between its lobbying positions and any stated policies, goals, or other public positions.”
- The means GRI-reporting companies should be disclosing the significant issues it lobbies on and any differences between its lobbying positions and its stated policies, goals and public positions.

Broad International Support for Lobbying Transparency

- The International Corporate Governance Network (ICGN) representing more than \$18 trillion in assets, supports lobbying disclosure and political disclosure as best practice, and supports disclosure of any amounts over \$10,000.¹⁸
- In May 2018, the Principles for Responsible Investment (PRI) launched a new guide on corporate climate lobbying to help investors engage with companies on their direct and indirect lobbying practices related to climate policy. Specifically, companies should be consistent in their policy engagement in all geographic regions and should ensure any engagement conducted by member trade associations on their behalf or with their support is aligned with company positions.¹⁹
- In October 2018, a \$2 trillion coalition of investors led by the Church of England pension board and Swedish pension fund AP7, sent letters to 55 large European companies, stating that lobbying on climate issues should be evaluated, managed and reported on transparently and noting it was unacceptable that companies counteract ambitious climate policy, either directly or through their trade associations.²⁰
- The OECD’s Principles for Transparency and Integrity in Lobbying find that a sound framework for transparency in lobbying is crucial to safeguard the integrity of the public decision-making process.²¹

AbbVie Has Its Lobbying Information and Could Easily Report It to Shareholders

- AbbVie claims that the “proposal is unnecessary, because AbbVie already makes extensive disclosures regarding our lobbying and political activities as required by law.” But this argument is not convincing, as AbbVie is required to report its federal and state lobbying and already has all of this information, so it could be readily provided to stockholders in a single report at minimal expense.

¹⁷ <https://www.globalreporting.org/standards/gri-standards-download-center/gri-415-public-policy-2016/>

¹⁸ <https://www.icgn.org/sites/default/files/ICGN%20Political%20Lobbying%20%26%20Donations%202017.pdf>

¹⁹ https://www.unpri.org/Uploads/g/v/q/PRI_Converging_on_climate_lobbying.pdf

²⁰ “Pension Funds Challenge Major European Emitters on Climate Lobbying,” Church of England, October 29, 2018, <https://www.churchofengland.org/more/media-centre/news/pension-funds-challenge-major-european-emitters-climate-lobbying>.

²¹ <http://www.oecd.org/gov/ethics/oecdprinciplesfortransparencyandintegrityinlobbying.htm>

Political Contributions Disclosure Rankings Do Not Measure Lobbying Disclosure

- The Board argues that Abbvie has been recognized as a “Trendsetter” in the 2018 CPA-Zicklin Index of Corporate Political Disclosure and Accountability, a report that measures political disclosure and accountability policies and practices of companies in the S&P 500. However, this argument is misleading since the Company’s CPA-Zicklin ranking has nothing to do with lobbying spending disclosure. The Company conflates electoral and lobbying spending disclosures in its Proxy Statement and implies that both issues are covered in the ranking. The fact that the Company touts being ranked as a trendsetter on the CPA-Zicklin Index, a measurement of transparency in political contributions but not lobbying, suggests that AbbVie could, in fact, become a leader in lobbying disclosure as well.

Lobbying Transparency: What Gets Disclosed Gets Managed.

- If AbbVie has nothing to hide, transparent disclosure would simply show that its lobbying is being done in the company and stockholders’ best interests.
- Knowing our company’s lobbying will be disclosed will ensure board and management oversight to safeguard that lobbying is being done in stockholder and AbbVie’s best interests.

The well-documented reputational risks of AbbVie’s lobbying and its inadequate lobbying disclosure policies highlight the critical need for the Company to improve its lobbying disclosures and increase transparency around its lobbying policies, procedures and spending details.

For all of the above reasons, we believe that AbbVie’s current lobbying disclosures are inadequate to protect stockholder interests. We urge you to vote FOR Proposal 5, the stockholder proposal requesting a report on the Company’s lobbying expenditures.

--

For questions regarding AbbVie Proposal No. 5 regarding lobbying disclosure, please contact Pat Miguel Tomaino, Director of Socially Responsible Investing, Zevin Asset Management, 617.742.6666, pat@zevin.com.
